Edition:
United Kingdom

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

3.02USD
8:59pm GMT
Change (% chg)

$-0.09 (-2.89%)
Prev Close
$3.11
Open
$3.08
Day's High
$3.13
Day's Low
$3.00
Volume
176,142
Avg. Vol
294,442
52-wk High
$3.93
52-wk Low
$1.85

Latest Key Developments (Source: Significant Developments)

Antares Pharma Enters Into Development Agreement With Pfizer
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA ENTERS INTO DEVELOPMENT AGREEMENT WITH PFIZER INC..ANTARES PHARMA - PFIZER TO PAY FOR DEVELOPMENT OF PRODUCT, TO BE RESPONSIBLE FOR OBTAINING FDA APPROVAL OF COMBINATION PRODUCT.ANTARES PHARMA INC - CO, PFIZER TO DEVELOP A COMBINATION DRUG DEVICE RESCUE PEN.ANTARES PHARMA - ANTARES TO RECEIVE ROYALTIES ON NET SALES ON COMBINATION PRODUCT.  Full Article

Antares Pharma Reports Q1 Loss Per Share Of $0.04
Tuesday, 8 May 2018 

May 8 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.04.Q1 REVENUE $12.7 MILLION VERSUS I/B/E/S VIEW $12.9 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.03 -- THOMSON REUTERS I/B/E/S.  Full Article

Antares Pharma Provides Xyosted™ Regulatory Update
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE.BELIEVES THAT IT DOES NOT NEED TO CONDUCT ANY NEW CLINICAL STUDIES TO SUPPORT RESUBMISSION.ANTARES PHARMA -ANTICIPATES RESUBMISSION TO INCLUDE RE-ANALYSES OF EXISTING DATA, ADDRESS LABELING, POTENTIAL POST-APPROVAL RISK MITIGATION STRATEGIES.ANTICIPATES SUBMITTING COMPLETE RESPONSE IN Q2 OF THIS YEAR.OFFICIAL MINUTES FROM TYPE A MEETING WITH FDA ON FEB. 21 HAVE BEEN RECEIVED.  Full Article

Antares Pharma Provides Xyosted Regulatory Update
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE.ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED.ANTARES PHARMA - REQUEST FOR MEETING WAS IN RESPONSE TO COMPLETE RESPONSE LETTER RECEIVED BY ANTARES REGARDING NEW DRUG APPLICATION FOR XYOSTED.  Full Article

Antares Pharma Q3 loss per share $0.03
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Antares Pharma Inc :Antares Pharma reports third quarter 2017 operating and financial results.Q3 loss per share $0.03.Q3 revenue $15.1 million versus I/B/E/S view $14 million.Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.Antares Pharma - ‍at September 30, 2017, cash, cash equivalents and short-term investments were $37.4 million compared to $27.7 million at December 31, 2016​.  Full Article

Antares Pharma receives complete response letter from FDA for Xyosted
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Antares Pharma Inc :Antares pharma receives complete response letter from the fda for Xyosted.‍CRL indicates that FDA cannot approve NDA in its present form​.‍FDA is concerned that Xyosted could cause a clinically meaningful increase in blood pressure​.‍CRL identified two deficiencies related to clinical data for Xyosted injection​.Complete response ‍letter also raised a concern regarding occurrence of depression and suicidality​.  Full Article

Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Antares Pharma Inc :Antares Pharma provides Xyosted™ regulatory update.Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​.Antares Pharma Inc - ‍intends to work with FDA to understand nature of deficiencies once identified.Antares Pharma Inc - ‍received a letter from FDA regarding Xyosted .Antares Pharma Inc - ‍ letter from U.S. FDA does not specify deficiencies identified with respect to review of Xyosted NDA​.Antares Pharma Inc - got letter on Oct 11 stating FDA identified deficiencies precluding continuation of discussion of labeling, postmarketing needs at this time​.  Full Article

Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Antares Pharma Inc ::Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals.Antares Pharma Inc - deal for ‍up to $14.5 million​.Antares - to sell worldwide rights, including certain fixed assets, for Zomajet needle-free auto injector device to Ferring Pharmaceuticals​.Antares - deal with Ferring generates non-dilutive cash which co intends to use to invest to support launch of Xyosted​.  Full Article

UPDATE 1-Antares Pharma's testosterone drug gets FDA approval

Oct 1 The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected.

No consensus analysis data available.